In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor
Open Access
- 25 June 2020
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (7), 1979-1987
- https://doi.org/10.3324/haematol.2020.248658
Abstract
Pharmacological induction of fetal hemoglobin (HbF) expression is an effective therapeutic strategy for the management of beta-hemoglobinopathies such as sickle cell disease. DNA methyltransferase (DNMT) inhibitors 5-azacytidine (5-aza) and 5-aza-2′-deoxycytidine (decitabine) have been shown to induce fetal hemoglobin expression in both preclinical models and clinical studies, but are not currently approved for the management of hemoglobinopathies. We report here the discovery of a novel class of orally bioavailable DNMT1-selective inhibitors as exemplified by GSK3482364. This molecule potently inhibits the methyltransferase activity of DNMT1, but not DNMT family members DNMT3A or DNMT3B. In contrast with cytidine analog DNMT inhibitors, the DNMT1 inhibitory mechanism of GSK3482364 does not require DNA incorporation and is reversible. In cultured human erythroid progenitor cells (EPCs), GSK3482364 decreased overall DNA methylation resulting in de-repression of the gamma globin genes HBG1 and HBG2 and increased HbF expression. In a transgenic mouse model of sickle cell disease, orally administered GSK3482364 caused significant increases in both HbF levels and in the percentage HbF-expressing erythrocytes, with good overall tolerability. We conclude that in these preclinical models, selective, reversible inhibition of DNMT1 is sufficient for the induction of HbF, and is well-tolerated. We anticipate that GSK3482364 will be a useful tool molecule for the further study of selective DNMT1 inhibition both in vitro and in vivo.Keywords
This publication has 51 references indexed in Scilit:
- Global DNA Demethylation During Mouse Erythropoiesis in VivoScience, 2011
- A Key Commitment Step in Erythropoiesis Is Synchronized with the Cell Cycle Clock through Mutual Inhibition between PU.1 and S-Phase ProgressionPLoS Biology, 2010
- Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseaseProceedings of the National Academy of Sciences of the United States of America, 2010
- Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzymeNucleic Acids Research, 2010
- A real-time assay for CpG-specific cytosine-C5 methyltransferase activityNucleic Acids Research, 2010
- Genetic complexity in sickle cell diseaseProceedings of the National Academy of Sciences of the United States of America, 2008
- DNA Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3BMolecular and Cellular Biology, 2008
- Developmental- and differentiation-specific patterns of human γ- and β-globin promoter DNA methylationBlood, 2007
- Correction of sickle cell disease by homologous recombination in embryonic stem cellsBlood, 2006
- Treatment with Azacitidine of Patients with End-Stage β-ThalassemiaThe New England Journal of Medicine, 1993